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Abstract Acute ischemic events occur most frequently at
dawn and in the early hours of the morning. The devel-
opment of these severe clinical events exhibits a temporal
relationship with changes in various hemodynamic, pro-
thrombotic, and hormonal processes. The authors highlight
not only these relationships but also the potential protective
effect of increased bradykinin levels and the inhibition of
different angiotensin II (AT-II) receptors (AT2, AT4)
against unfavorable prothrombotic influences, which—
based on studies to date—decreases the risk of acute car-
diovascular events. Comparisons are presented between the
different effects of angiotensin-converting enzyme inhibi-
tors and angiotensin receptor blockers on factors that
influence thrombus formation and myocardial infarction
risk.
Key Points
The majority of coronary events generally occur at
dawn and in the early morning, a timing that may
also be relevant to their prevention.
The risk of acute myocardial events is significantly
influenced by prothrombotic, hormonal, and
hemodynamic processes that occur in the human
body according to circadian rhythms.
While the blood pressure-lowering effects of
angiotensin-converting enzyme inhibitors and
angiotensin receptor blockers (ARBs) should be
considered, so too should all other differences that
may protect against a plaque rupture leading to
myocardial infarction.
1 Introduction
Ischemic heart disease is one of the most frequent diseases
worldwide, and cardiovascular (CV) diseases are among
the leading causes of death in developed industrial coun-
tries [1, 2]. Progressive coronary atherosclerosis is the main
pathological base of ischemic heart disease, eventually
resulting in overt disease. Two main forms of its mani-
festation are differentiated in clinical practice: stable coro-
nary artery disease (SCAD) and acute coronary syndrome
(ACS), which includes unstable angina (UA) pectoris and
various forms of myocardial infarction (MI) such as ST-
segment elevation myocardial infarction (STEMI) and non-
ST-segment elevation myocardial infarction (NSTEMI)
[3]. As we know, most acute coronary events are underlain
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by rupture or erosion of plaques, which block the blood
supply at given myocardial areas by thrombus formation.
In patients who have experienced an acute MI (AMI), the
incidence of plaque rupture (70–75 %) is higher than that
of plaque erosion (20–25 %) [3, 4]. The mechanisms
leading to unstable plaques are complex, and several local
and systemic factors play a part [5]. However, the majority
of coronary events occur at dawn and in the early hours of
the morning, which may also be of considerable relevance
in terms of prevention [6]. The development of acute MI
[7] and the closely related mortality shows a significant
peak primarily in the period between 6 a.m. and 8 a.m. [8];
the risk of developing events then decreases to the early
afternoon (Fig. 1).
2 Importance of Dawn and the Early Morning
Hours and Roles of the Acute Risk Factors
Although the development of unstable atherosclerotic
lesions is regarded as a key step in the initiation of ACS,
the mechanism leading to it is only partly understood, but
can be concretized with difficulty by highlighting some of
its major elements [5, 9]. Plaque instability is determined
mainly by a complex of inflammatory processes and
immune system activation in the plaque, as well as
thrombogenic factors in the circulating blood [10]. In the
presence of a vulnerable plaque, the prothrombotic pro-
cesses that lead to the rupture of the plaque may be trig-
gered by stressors of a physical (e.g., excessive exercise),
mental (e.g., workplace stress, anxiety, anger), or chemical
(e.g., alcohol, narcotic) nature [11]. However, these risks
are characteristic of the active morning and even afternoon
parts of the day and do not explain why acute conditions
peak with dawn and in the early hours of the morning.
Nevertheless, the development of ACS may be signifi-
cantly determined by transient biological/physiological
changes that follow a circadian rhythm and predominate in
the early morning [12]. In addition to the increased sym-
pathetic tonus, the prothrombotic response may be aug-
mented by the dawn increase in blood pressure, platelet
activation, and coagulability, and disrupted fibrinolysis
balance. These changes acting on the short term are the
‘acute risk factors’ that represent the final impetus in the
process leading to plaque instability and rupture, and may
thereby increase the risk of CV events developing [13].
The early morning increase in blood pressure and heart
rate enhance myocardial oxygen demand while coronary
flow is decreased [14]. The number and activity of circu-
lating platelets may also fluctuate according to circadian
rhythms, where catecholamines may also play a role
[15, 16]. The activation of coagulation factors (e.g., Factor
VII, fibrinogen, prothrombin), and the decreased morning
activity of fibrinolytic system elements (plasminogen
activator inhibitor-1 [PAI-1] and tissue plasminogen acti-
vator [t-PA]) also follow a circadian rhythm [15–18]
(Fig. 2). The differences between the two main processes
of cardiac oxygen demand/supply and coagulation/fibri-
nolytic systems may underlie the development of morning
ACS [17, 18]. Results of intravascular ultrasonography
(IVUS) angiographies performed prior to coronary inter-
ventions demonstrate that the circadian rhythm of AMI can
be attributed mostly to the increase in the incidence of
plaque ruptures in the morning [19].
Thus, the interactions between primary triggers and
acute risk factors (Fig. 3) represent a critical period for
acute CV events [13]. Acute risk factors that follow a
circadian pattern can be classified into four main groups:
hemodynamic effects, prothrombotic conditions, inflam-
matory reactions, and neurohormonal influences. The
effects of apparently unimportant changes such as these
may be superposed to disorders already caused by chronic
risk factors (e.g., the presence of unstable atherosclerotic
plaques due to dyslipidemia and hypertension) and may
initiate/enhance the triggered processes that lead to the
acute events.
3 Relationship Between Hypertension
and the Prothrombotic State
Elevated systolic blood pressure ([140 mmHg) is one of
the most important risk factors of coronary heart disease
(CHD) [20]. Blood pressure also follows a characteristic
circadian pattern in healthy people. In hypertensive
Fig. 1 Circadian rhythm of coronary heart disease mortality and
acute myocardial infarction that shows a significant peak primarily in
the period between 6 a.m. and 8 a.m. [6–8]. CHD coronary heart
disease
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patients, a 24-h blood pressure profile shows changes that
result in an increased variability and a morning rise in
blood pressure [14, 18]. Raised dawn and early morning
blood pressure is one of the most significant acute risk
factors that places a greater hemodynamic burden on the
coronary circulation and is associated with the activation of
several neurohumoral systems [13]. The morning surge in
blood pressure represents the greatest danger, primarily for
‘non-dipper’ or ‘extreme dipper’ patients; in the former this
is due to the pressure load that begins relatively early, at
dawn, and lasts for 8–10 h, the latter because of the dan-
gerously steep increase in blood pressure [21]. The flow-
mediated vasodilatation (FMD) that reflects the functional
state of the vessels shows no fluctuation in a healthy
population, whereas it fluctuates together with ischemic
episodes and is worse in the early morning period in
patients with CHD and angina. This may be related to risk
factors that follow circadian rhythms [22].
The shearing force on the vascular wall due to hyper-
tension, turbulent flow, developing endothelial dysfunc-
tion, atherosclerotic vessel damage, vascular inflammation,
and imbalance between hemostasis elements represents a
significant prothrombotic and CV risk [16]. For instance,
the level of PAI-1 that inhibits the initiation of fibrinolysis
is highest in the early morning hours, which can be cor-
related with the critical period for coronary events [7, 22].
On the other hand, the levels of t-PA responsible for the
initiation of fibrinolytic processes are also lowest in the
critical dawn period and highest when the risk of devel-
oping CV events is the lowest [13, 17, 18, 23]. Platelet
aggregability also shows diurnal changes and is at its
highest in the early morning hours [24].
Fig. 2 Circadian rhythm of




that represents a critical period
for acute cardiovascular events
[15–18]
Fig. 3 Potential conjunction of
triggers (workload, stress,





were ‘superposed’ to disorders
already caused by the chronic
risk factors and initiate the acute
coronary events [13]. BP blood
pressure, CNS central nervous
system, HR heart rate, PAI-1
plasminogen activator
inhibitor-1
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Fig. 4 Presumed differences in mechanisms of action of angiotensin-
converting enzyme inhibitors and angiotensin receptor blockers. The
elevated levels of plasminogen activator inhibitor-1 and decreased
tissue plasminogen activator activity affects coronary circulation,
causing coronary heart disease. Evidence suggests that bradykinin
(that increased by angiotensin-converting enzyme inhibitors only)
stimulates tissue plasminogen activator synthesis and AT4 receptors
(that is inhibited by angiotensin-converting enzyme inhibitors only
also) results in increased expression of plasminogen activator
inhibitor-1 secretion in endothelial cells. This mode of action of
angiotensin-converting enzyme inhibitors explains their ability to
reduce acute coronary events [25–27]. ACE(I) angiotensin-converting
enzyme (inhibitor), AT angiotensin, NO nitric oxide, PAI-1 plas-
minogen activator inhibitor-1, PGI2, prostaglandin I2, t-PA tissue
plasminogen activator
Fig. 5 Different effects of the
angiotensin-converting enzyme
inhibitor perindopril and the
angiotensin receptor blocker
losartan on factors influencing
thrombus formation [37–39]. NS
not significant, PAI-1
plasminogen activator inhibitor-
1, t-PA tissue plasminogen
activator
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Summing up, one may state that the well-known circadian
rhythm of prothrombotic and other ‘acute risk factors’ may
initiate processes, upon the effects of triggers, which together
may increase the chance for plaque rupture in patients with a
high CV risk. Renin–angiotensin system (RAAS) inhibitors,
which—in addition to their antihypertensive effect—can also
reduce plaque instability due to acute risk factors, may
reduce the chance of atherosclerosis-based CV events and the
risk of developing an AMI to a greater extent.
4 Differences Between Angiotensin-Converting
Enzyme Inhibitors and Angiotensin Receptor
Blockers
ACEIs and ARBs are the two most often used groups of
RAAS inhibitors. The putative difference between the two
groups may be related to their differing mechanisms of
action. The dissimilarity of therapeutic usefulness may be
due partly to the beneficial effects associated with
increased bradykinin levels (with ACEIs) and the effects
on other angiotensin (AT)-II receptors (AT2, AT4) exerted
as subsequent activities by the increasing AT-II levels
(with ARBs) [25–27] (Fig. 4).
Several studies in ACEIs have demonstrated that they
reduce endothelial dysfunction, inflammatory reactions,
cell adhesion, and cell apoptosis [28–30]. In addition to
their antithrombotic and antiatherosclerotic effects, they
also play a role in the restoration of fibrinolytic balance,
exerted in part via the bradykinin-dependent (nitric oxide
[NO]) processes, which can be considered a particular
property of ACEIs [28, 31–33]. These mechanisms alone
apparently explain the greater efficacy of ACEIs with high
tissue affinity (e.g., perindopril, ramipril) in the reduction
of AMI risk [29, 34, 35].
Table 1 Differences between mechanisms of action of angiotensin-
converting enzyme inhibitors and angiotensin receptor blockers in
relation to endothelial function and thrombosis risk [41]
ACEI ARB
Reduces endothelial dysfunction ? ?
Reduces inflammation ? -
Reduces cell adhesion ? ?
Antithrombotic effect ? ±
Anti-atherosclerotic effect ? ?
Reduces cell apoptosis ? -
Strengthens fibrinolitic balance ? ±
ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin
receptor blocker
Fig. 6 Different effects of angiotensin-converting enzyme inhibitors
and angiotensin receptor blockers on the risk of myocardial infarction
compared with placebo or active compounds in some clinical trials
[39–47]. AMI acute myocardial infarction, CCB calcium channel
blocker, CI confidence interval, HR hazard ratio
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The binding of ARB to the AT1 type of AT-II receptors
causes a compensatory increase of AT-II levels. The free
AT-II may bind to other AT-II receptors (AT2, AT3, AT4),
which mediate effects resulting in instability and rupture of
the plaques [25, 36]. If we compare the effects of
perindopril (an ACEI with high tissue affinity), losartan,
and telmisartan (ARBs) on the coagulative/prothrombotic
factors (PAI-1, plasma fibrinogen, t-PA), we can see sig-
nificant differences [37–40]. Perindopril exerts more
favorable effects than losartan on several parameters
(Fig. 5).
Ferrari and colleagues [26, 41] compared the mecha-
nisms of action of the two groups of RAAS and their
effects on endothelial and vascular functions in detail.
They found several differences between the two groups in
terms of factors that play a role in functional and structural
changes of the vessels. While ACEIs have practical bene-
ficial effects on all parameters, ARBs have only partially
beneficial effects in relation to, for example, antithrombotic
activity or inflammatory parameters (Table 1).
The surprising effects observed in some clinical studies
can be explained by the different effects on prothrombotic
factors. The risk of AMI was found to increase with the use
of ARBs. This was significant in some cases, in others it
was simply a trend compared with control therapies
(Fig. 6) [42–49].
The results of ONTARGET also suggest ACEIs and ARBs
have different effects and mechanisms of action: the risk of
AMI showed a tendency to be lower in the ACEI ramipril
group (relative risk [RR] 1.07; 95 % confidence interval [CI]
0.94–1.22); although the mean systolic 24-h blood pressure
was significantly (3 %) lower in the ARBgroup,which can be
regarded as clinically significant [50, 51].
5 Conclusion
Several studies have confirmed that ACEIs effectively
reduce blood pressure, including in the critical
night/morning period. In addition, they effectively reduce
the effects of prothrombotic factors, which follow a cir-
cadian rhythm, possibly determined by bradykinin-depen-
dent (NO) mechanisms that can be regarded as specific to
this group. In this context, the beneficial effects of ACEIs
that reduce the risk of AMI have been demonstrated in
several large studies.
Thus, not surprisingly, based on the results of studies
with ACEIs and ARBs, both European (European Society
of Cardiology [ESC]) and American (American College of
Cardiology Foundation [ACCF]/American Heart Associa-
tion [AHA]) guidelines prefer ACEIs for the prevention of
recurring coronary events in patients after an AMI [52, 53].
The use of ARBs is only indicated when ACEIs are con-
traindicated for any reason.
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